INS and Insulin resistance: Clinically, these 2 indices complement each other: HOMA-IR identifies patients with early insulin resistance, who may benefit from lifestyle or pharmacologic interventions targeting insulin sensitivity (e.g., metformin, TZDs), whereas HOMA-β helps assess residual β-cell capacity, guiding decisions on whether to initiate insulin therapy or incretin-based agents.